

In the claims

Cancel claims 1-18.

Add new claims 19-38.

We claim:

19. A composition comprising nimesulide and 17% to 59% by weight of a glyceryl monoolein-solvent-phase, wherein the nimesulide is in the glyceryl monoolein-solvent-phase.
20. The composition of claim 19, wherein glyceryl monoolein-solvent phase has a liquid crystal structure.
21. The composition of claim 19, wherein the nimesulide comprises 0.1% to 5% by weight of the composition.
22. The composition of claim 19, further comprising a non-aqueous solvent.
23. The composition of claim 22, wherein the non-aqueous solvent is selected from the group consisting of diethylene glycol monoethyl ether (DGME) and ethanol.
24. The composition of claim 22, further comprising a gelling agent.
25. The composition of claim 24, wherein the gelling agent is hydroxypropylcellulose.
26. A process, comprising:
  - a. dissolving nimesulide in a non-aqueous solvent;
  - b. heating the nimesulide and the non-aqueous solvent of step a to 30° to 90°C;
  - c. heating glyceryl monoolein to 35° to 55°C;

d. mixing the nimesulide and the non-aqueous solvent of step a with the glyceryl monoolein of step c; and,

e. allowing the mixture of step d to cool to room temperature with constant agitation.

27. The process of claim 26, wherein a gelling agent is added at a step selected from the group consisting of step a, step c, step d and step e.

28. A process comprising:

- a. dissolving glyceryl monoolein in a non-aqueous solvent;
- b. heating the glyceryl monoolein and the non-aqueous solvent of step a to 30° to 90°C;
- c. mixing nimesulide into the glyceryl monoolein and the non-aqueous solvent of step b; and,
- d. allowing the mixture of step c to cool to room temperature with constant agitation.

29. The process of claim 28, wherein a gelling agent is added at a step selected from the group consisting of step a, step c and step d.

30. A method, wherein a composition comprising nimesulide and 17% to 59% by weight of a glyceryl monoolein-solvent-phase, wherein the nimesulide is in the glyceryl monoolein-solvent phase, is administered to an animal in need of treatment for an indication selected from the group consisting of pain, inflammation and stiffness in amount effective to treat the animal.

31. The method of claim 30, wherein glyceryl monoolein-solvent phase has a liquid crystal structure.

32. The method of claim 30, wherein the nimesulide comprises 0.1% to 5% by weight of the composition.